Drug-eluting stent graft

1. A drug-eluting stent graft comprising:

(a) a drug;

(b) a drug-retaining agent; and

(c) a stent graft;

wherein the drug (a) comprises (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylidenaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof;

wherein the drug-retaining agent (b) is at least one selected from the group consisting of fibrin, gelatin, collagen and hyaluronic acid;

wherein the stent graft (c) is an artificial blood vessel used for intravascular surgery;

wherein the stent graft (c) has a structure in which a metal wire mesh tube is coated inside and/or outside thereof with a resin;

wherein the resin is in the form of fabric which has a thickness in the range of 10 to 160 μm;

wherein a mixture containing the drug (a) and the drug-retaining agent (b) is coated on the outside (the side that contacts the intra-arterial wall) of the stent graft (c); and

wherein the drug (a) promotes fixation of the stent graft (c) to an aorta wall.

2. The drug-eluting stent graft according to claim 1 , wherein the drug (a) is a slow-release formulation.

3. The drug-eluting stent graft according to claim 2 , wherein the slow-release formulation further comprises a biodegradable polymer.

4. The drug-eluting stent graft according to claim 1 , wherein the drug (a) is a microsphere formulation.

5. The drug-eluting stent graft according to claim 3 , wherein the slow-release formulation is a microsphere formulation.

6. The drug-eluting stent graft according to claim 3 , wherein the biodegradable polymer is at least one selected from the group consisting of polylactic acid, polyglycolic acid, a lactic acid-glycolic acid copolymer, and a mixture thereof.

7. The drug-eluting stent graft according to claim 5 , wherein the biodegradable polymer is at least one selected from the group consisting of polylactic acid, polyglycolic acid, a lactic acid-glycolic acid copolymer, and a mixture thereof.

8. The drug-eluting stent graft according to claim 5 , wherein the biodegradable polymer has a weight average molecular weight of 6,000 to 50,000.

9. The drug-eluting stent graft according to claim 5 , wherein the microsphere formulation contains (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylidenaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid or a salt thereof at 5 to 30% by weight.

10. The drug-eluting stent graft according to claim 5 , wherein the microsphere formulation has an average particle diameter of 15 to 50 μm.

11. The drug-eluting stent graft according to claim 1 , wherein the drug-retaining agent (b) is at least one selected from the group consisting of fibrin, atelocollagen and gelatin.

12. The drug-eluting stent graft according to claim 1 , wherein the stent graft (c) includes a mixture comprising gelatin and a micro sphere formulation containing (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylidenaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid, the mixture being applied on an outside of the stent graft.

13. The drug-eluting stent graft according to claim 1 , which is used to be placed at an aneurysmal portion in a mammal.

14. The drug-eluting stent graft according to claim 1 , which is used to prevent a stent graft-related complication.

15. The drug-eluting stent graft according to claim 14 , wherein the stent graft-related complication is migration and/or endoleak.

16. The drug-eluting stent graft according to claim 1 , wherein the stent graft (c) is an artificial blood vessel used for aneurysm surgery.

17. The drug-eluting stent graft according to claim 1 , wherein the resin is in the form of fabric which has a thickness in the range of 20 to 95 μm.